Skip to content

Study · Not a test of the peptide alone · 2025

3 results

Case Report: Clinical pharmacist prescriber in depression treatment in primary care settings: clinical case focused on prescribing practice.

Stuhec M

Frontiers in psychiatry28 Aug 2025Cited by 1 (Europe PMC)

PMID40950770 (opens in a new tab)PMCIDPMC12423072 (opens in a new tab)DOI10.3389/fpsyt.2025.1677152 (opens in a new tab)PepBankPUB-40950770
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

IntroductionPharmacotherapy of depression represents a significant challenge in the management of depression in primary care. Although effective treatments have been available, many patients are still not adequately managed. Clinical pharmacists represent one of the possible strategies in the management, although this practice is rarely seen outside the United Kingdom and the United States.AimThe aim of the case was to evaluate the impact of clinical pharmacist prescribers on depression treatment.MethodsA longitudinal, observational, case-based medication review by a pharmacist prescriber was conducted for a 63-year-old Slovenian patient in a primary care ambulatory setting. The review included three structured medication review assessments performed by a clinical pharmacist prescriber at defined intervals: first observation, two months post-intervention, and six months after first observation. The pharmacists conducted medication reviews and prescribed medications like physicians, operating within a collaborative practice agreement as dependent prescribers. Predefined outcomes included diabetes management (HbA1c and blood glucose), lipid levels (S-LDL), pain (Visual Analogue Scale [VAS]), depression (Patient Health Questionnaire-9 [PHQ-9]), and quality of life (assessed via EQ-5D-VAS). The patient's complete medication regimens were reviewed, focusing on dosage appropriateness, indication matching, potential drug-drug interactions, and medication adherence.ResultsA 63-year-old male Slovenian patient diagnosed with depression, type 2 diabetes with polyneuropathy, and hypothyroidism underwent two medication reviews between December 2024 and July 2025. The pharmacist prescribed amitriptyline and semaglutide (accepted by the patient's physician). Notable improvements were observed in glycemic control (HbA1c reduced from 9.9% to 8.2%), and quality of life (EQ-5D-VAS score improved from 30/100 to 80/100). Depression symptoms also resolved, with the PHQ-9 score improving from 11 to 4.ConclusionsThis case study demonstrates that interventions by a clinical pharmacist prescriber during the medication review process resulted in improved clinical outcomes in the treatment of depression, as well as enhanced quality of life. It represents an important contribution to the development of pharmacist prescribing roles in depression management within primary care settings outside of the United Kingdom and the United States.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 63-year-old man with depression and type 2 diabetes, HbA1c fell after a pharmacist prescribed amitriptyline and semaglutide.

    In plain wordsIn one man with depression and diabetes, blood sugar control improved after a pharmacist prescribed amitriptyline and semaglutide; the drugs' separate effects are unknown.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c baseline
    9.9%
    first review
    HbA1c later
    8.2%
    later review

    Source sentences

    Summary
    glycemic control (HbA1c reduced from 9.9% to 8.2%
    2 context sentences
    Summary · context
    A 63-year-old male Slovenian patient diagnosed with depression, type 2 diabetes with polyneuropathy, and hypothyroidism underwent two medication reviews between December 2024 and July 2025.
    Summary · context
    The pharmacist prescribed amitriptyline and semaglutide (accepted by the patient's physician).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 63-year-old man with depression and type 2 diabetes, the EQ-5D-VAS quality-of-life score rose after a pharmacist prescribed amitriptyline and semaglutide.

    In plain wordsIn one man with depression and diabetes, quality of life improved after a pharmacist prescribed amitriptyline and semaglutide; the drugs' separate effects are unknown.

    Peptide
    Semaglutide
    Outcome
    IncreaseQuality of life (EQ-5D-VAS)
    Study

    n = 1

    Outcome group
    Exercise and physical function · Whole body

    Measurements

    EQ-5D-VAS baseline
    30 /100
    first review
    EQ-5D-VAS later
    80 /100
    later review

    Source sentences

    Summary
    quality of life (EQ-5D-VAS score improved from 30/100 to 80/100
    2 context sentences
    Summary · context
    A 63-year-old male Slovenian patient diagnosed with depression, type 2 diabetes with polyneuropathy, and hypothyroidism underwent two medication reviews between December 2024 and July 2025.
    Summary · context
    The pharmacist prescribed amitriptyline and semaglutide (accepted by the patient's physician).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a 63-year-old man with depression and type 2 diabetes, the PHQ-9 score fell after a pharmacist prescribed amitriptyline and semaglutide.

    In plain wordsIn one man with depression and diabetes, depression symptoms resolved after a pharmacist prescribed amitriptyline and semaglutide; the drugs' separate effects are unknown.

    Peptide
    Semaglutide
    Outcome
    DecreaseDepression symptoms (PHQ-9)
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood

    Measurements

    PHQ-9 baseline
    11 points
    first review
    PHQ-9 later
    4 points
    later review

    Source sentences

    Summary
    Depression symptoms also resolved, with the PHQ-9 score improving from 11 to 4.
    2 context sentences
    Summary · context
    A 63-year-old male Slovenian patient diagnosed with depression, type 2 diabetes with polyneuropathy, and hypothyroidism underwent two medication reviews between December 2024 and July 2025.
    Summary · context
    The pharmacist prescribed amitriptyline and semaglutide (accepted by the patient's physician).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.